Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TXIKN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2015177360A1 ADC-Natalizumab S375C
|
|||||
| Synonyms |
WO2015177360A1_ADC Natalizumab S375C
Click to Show/Hide
|
|||||
| Organization |
Byodes Private Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.7
|
|||||
| Antibody Name |
Natalizumab S375C
|
Antibody Info | ||||
| Antigen Name |
Integrin alpha-4 (ITGA4)
|
Antigen Info | ||||
| Payload Name |
seco-DUBA
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Duocarmazine
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.